Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03800030 · ClinicalTrials.gov registry record · NA

Effect of Cross Frequency tACS on Cognitive Control

A NA study of Executive Function and Cognitive Control, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
26
Enrollment target
1
Study location

NCT03800030: Completed NA study of Executive Function and Cognitive Control, sponsored by University of North Carolina, Chapel Hill.

NCT03800030 is a NA study of Executive Function and Cognitive Control that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 26 participants, below the 144-participant average among 5 other Executive Function trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03800030, a NA study of Executive Function and Cognitive Control, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

Investigation of frequency specific transcranial alternating current stimulation on cognitive control signals in frontal cortex

Primary Outcome

For low abstraction conditions, subjects must memorize a color to button mapping. For high abstraction conditions, subject must make a perceptual judgement on the similarity of two objects based on either texture or shape as cued by a color. The reaction time difference between high and low abstraction conditions was hypothesized to decrease when delta-beta tACS was delivered. As a control for the placebo effect of stimulation, the difference between delta-beta tACS and sham tACS, or placebo, wa

Interventions

  • DEVICE Sham tACS
  • DEVICE Theta-gamma tACS
  • DEVICE Delta-beta tACS

Study Locations (1)

North Carolina

  • University of North Carolina, Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2018-10-07
Est. Completion 2019-07-25
Phase NA

What the finished NCT03800030 record still lists

NCT03800030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 144-participant average among 5 other Executive Function trials with a reported enrollment target (82% lower).

The record links to 2 conditions, with Executive Function appearing as the primary indexed condition, and to 3 interventions - of which Sham tACS is the first listed.

NCT03800030 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT03800030 about?

NCT03800030 is a clinical study titled "Effect of Cross Frequency tACS on Cognitive Control". Investigation of frequency specific transcranial alternating current stimulation on cognitive control signals in frontal cortex

What is the current status of trial NCT03800030?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2018-10-07. Estimated completion is 2019-07-25.

What conditions does trial NCT03800030 study?

This clinical trial studies the following conditions: Executive Function, Cognitive Control.

What interventions are being tested in trial NCT03800030?

The interventions under investigation include: Sham tACS (DEVICE), Theta-gamma tACS (DEVICE), Delta-beta tACS (DEVICE).

Who is sponsoring clinical trial NCT03800030?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03800030 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Executive Function

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03800030, the US trial registry maintained by the National Library of Medicine. NCT03800030 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.